ArticleAmerican journal of translational research2025
Efficacy, safety, and vascular endothelial function improvement of enalapril maleate-folic acid tablets in H-Type hypertension.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical application value of Enalapril Maleate (EM)-Folic Acid (FA) Tablets in the treatment of H-type hypertension (HTHT), with a focus on evaluating its therapeutic efficacy, safety, and regulatory effects on vascular endothelial function.
methodsA retrospective analysis was conducted on 127 HTHT patients treated between March 2022 and January 2025. Patients were allocated into two groups: a control group (n=60) receiving EM monotherapy and a research group (n=67) receiving the EM-FA therapy. This study analyzed: ① overall therapeutic outcomes; ② blood pressure control; ③ stroke incidence; ④ drug-related adverse events; ⑤ lipid metabolism; ⑥ homocysteine (Hcy) levels; ⑦ vascular endothelial function; ⑧ serum inflammatory markers; and ⑨ hemorheological parameters.
resultsCompared with the control group, the research group exhibited superior post-treatment outcomes. Specifically, overall treatment efficacy was improved; blood pressure control was more effective; lipid profiles improved significantly; Hcy levels decreased more significantly; vascular endothelial function was better restored; inflammatory factor levels decreased more substantially; hemorheological parameters were optimized; and the incidences of stroke and drug-related adverse events were notably reduced.
conclusionsEM-FA Tablets provide significant therapeutic benefits in managing HTHT, with enhanced safety and notable improvements in vascular endothelial function, underscoring their potential for widespread clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.